<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00891748</url>
  </required_header>
  <id_info>
    <org_study_id>001:CD40L</org_study_id>
    <secondary_id>2006-000985-34</secondary_id>
    <nct_id>NCT00891748</nct_id>
  </id_info>
  <brief_title>Safety Study on AdCD40L Gene Therapy for Bladder Cancer</brief_title>
  <official_title>A Phase I/IIa Study of Dose-escalating Intravesical AdCD40L Instillation in Urinary Bladder Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to evaluate the feasibility of three instillations of
      immunostimulating gene therapy (AdCD40L) in patients with urinary bladder cancer. Tolerance,
      toxicity and immunological parameters will be evaluated during and post treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Continously during therapy and at follow up 30d</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Continously during treatment and at follow up 30d</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>AdCD40L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>AdCD40L</intervention_name>
    <description>Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter</description>
    <arm_group_label>AdCD40L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven diagnosis of transitional cell carcinoma of the bladder

          -  ECOG 0-2

          -  18 years of age or older

          -  signed informed consent

          -  for the Phase I part: patient scheduled for cystectomy

        Exclusion Criteria:

          -  Woman of childbearing potential (fertile woman)

          -  Other malignancy within 5 years of study, except for non-melanoma skin cancer

          -  Metastatic disease

          -  Previous exposure to any intravesical therapy for bladder cancer: within 3 months for
             chemotherapy and within 6 months for BCG therapy.

          -  Previous pelvic radiation or treatment with any cytotoxic, immunologic or
             chemotherapeutic agent for non-malignant conditions within 5 years of study.

          -  Clinically abnormal hepatic, renal or bone marrow function, or coagulation disorders
             in the opinion of the investigator.

          -  Chronic urinary tract infections.

          -  Serous infection of G.U. surgery, except for bladder cancer, within 1 month of study
             requiring more than 3 days of hospital care.

          -  Vesical capacity &lt;150mL and/or vesical obstruction with residual &gt;150 mL after
             spontaneous voiding.

          -  Previous exposure to any experimental drug within 3 months from enrolment.

          -  Any significant medical or psychiatric illness that would prevent the patient from
             giving informed consent of from following the study procedures.

          -  Patients who presently have urothelial cell carcinoma of the upper G.U. tract

          -  Patients with systemic autoimmune disease

          -  Patients that do not consent to that tissue and blood samples are stored in a biobank

          -  Treatment with systemically administered corticosteroids and NSAID within 4 weeks
             prior to first study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per-Uno Malmstrom, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital, Uppsala, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>April 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2009</study_first_posted>
  <last_update_submitted>January 15, 2010</last_update_submitted>
  <last_update_submitted_qc>January 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Thomas H Totterman</name_title>
    <organization>Uppsala University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

